Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2018 | Checkpoint inhibitors for head and neck cancer in the definitive setting?

Barbara Burtness • 9 Nov 2018
ESMO 2018
Head and Neck Cancer Nivolumab Pembrolizumab

Barbara Burtness, MD, of Yale School of Medicine, New Haven, CT, talks about the current survival benefit of early pembrolizumab exposure in recurrent/metastatic head and neck squamous cell carcinoma (HNSCCO and its potential applications in definitive treatment. Its combination with chemo-radiation, along with other immune checkpoint inhibitors are currently being studied. This interview took place at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

More from Barbara Burtness

0:47
Novel KRAS-targeting agents on the horizon
Barbara Burtness • 7 Aug 2022
0:35
Data on KRAS inhibitors in lung cancer at WCLC 2022
Barbara Burtness • 7 Aug 2022
10:08
Evolving role of HER2 targeted therapies in gastroesophageal cancers
Barbara Burtness • 28 May 2020
4:11
CDKN2A and TP53 mutation in HPV-negative HNSCC
Barbara Burtness • 28 May 2020

Related Videos

1:03
Challenges in implementing liquid biopsies for head and neck cancer
Mouadh Barbirou • 7 Apr 2024
2:43
Molecular profiling of tumor biomarkers in head and neck cancer
Mouadh Barbirou • 7 Apr 2024
1:40
The future of squamous cell carcinoma research at ESMO Asia 2023
Brian Henick • 6 Dec 2023
0:54
The role of immunotherapy in PD-L1 low advanced squamous cell carcinoma
Brian Henick • 6 Dec 2023
The content of VJOncology is intended for healthcare professionals